10-Q: Bausch + Lomb Reports Q1 2026 Results, Revenue Up 9%

Bausch + Lomb Corporation announced its first quarter 2026 financial results, reporting a 9% increase in total revenues to $1.244 billion, driven by favorable foreign currency impacts, increased pricing, and higher volumes across key segments.

Summary

• Bausch + Lomb Corporation reported first quarter 2026 revenues of $1.244 billion, a 9% increase compared to $1.137 billion in the first quarter of 2025.
• The revenue growth was driven by a $42 million favorable impact from foreign currencies, a $38 million increase in net realized pricing, and a $29 million increase in volumes.
• The Vision Care segment saw an 8% revenue increase to $711 million, Pharmaceuticals segment revenue grew 14% to $305 million, and Surgical segment revenue increased 7% to $228 million.
• The company reported a net loss of $70 million for the quarter, an improvement from a net loss of $211 million in the prior year period.
• Operating income improved significantly to $33 million from an operating loss of $83 million in the prior year.
• The company ended the quarter with $279 million in cash and cash equivalents and restricted cash.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with significant revenue growth and a substantial improvement in operating income and net loss, indicating a strengthening financial position and effective operational management.

Positives

• Total revenues increased by 9% to $1.244 billion in Q1 2026 compared to $1.137 billion in Q1 2025.
• Favorable foreign currency impacts contributed $42 million to revenue growth.
• Net realized pricing increased by $38 million, primarily from Vision Care and Pharmaceuticals segments.
• Volume increases contributed $29 million to revenue growth, mainly from Pharmaceuticals and Vision Care segments.
• The Pharmaceuticals segment showed strong growth with a 14% revenue increase to $305 million.
• Operating income improved substantially to $33 million from a loss of $83 million in the prior year.
• Net loss narrowed to $70 million from $211 million in the prior year.
• Cost of goods sold as a percentage of product sales decreased to 38.9% from 42.5% in the prior year.
• Selling, general, and administrative expenses decreased by 3% to $544 million.
• Research and development expenses increased by 17% to $101 million, indicating investment in future growth.
• The company ended the quarter with $279 million in cash and cash equivalents and restricted cash.

Negatives

• The company reported a net loss of $70 million for the quarter.
• Despite improvements, the company still incurred a net loss attributable to Bausch + Lomb Corporation of $71 million.
• The company's debt obligations remain substantial, with total long-term debt at $5.039 billion net of issuance costs.
• The company's credit ratings are in the 'B' category, indicating a higher risk profile.
• The company faces ongoing litigation, including product liability and antitrust cases, which could result in material adverse effects.

Risks

• Adverse economic conditions, including inflation and interest rates, could negatively impact revenues and margins.
• Tariffs, trade policies, and global supply chain disruptions pose risks to manufacturing, distribution, and operational costs.
• The company faces challenges as an independent entity post-IPO, including potential conflicts of interest for directors and officers who also serve BHC.
• The proposed separation from Bausch Health Companies Inc. (BHC) carries significant risks and uncertainties regarding its completion, timing, and benefits.
• Ongoing or potential future litigation, claims, challenges, and regulatory investigations related to the IPO and separation could be costly.
• Legislative and policy efforts aimed at reducing healthcare costs could lead to new mandatory rebates, discounts, or pricing restrictions.
• Regulatory oversight and potential actions by agencies like the FDA could impact products and facilities.
• Downgrades in credit ratings could increase borrowing costs and limit access to debt capital.
• Changes in assumptions for impairment analyses could lead to impairment charges on goodwill or other intangible assets.
• Risks associated with acquisitions, including integration challenges and realization of expected benefits.
• Uncertainties in the acquisition and launch of new products, including regulatory approvals and market acceptance.
• Competition from larger companies with greater resources.
• Reimbursement decisions by government authorities and third-party payors can impact product pricing and sales.
• Consolidation among wholesalers, retail drug chains, and other customer groups could affect business relationships.
• Potential for product recalls or withdrawals from the market.
• Risks associated with international operations, including emerging markets and differing regulatory regimes.
• Geopolitical instability and conflicts in regions like the Middle East and Eastern Europe could impact operations and revenues.
• The introduction of generic or biosimilar competitors could significantly decrease product sales.
• The expense, timing, and outcome of pending or future legal and governmental proceedings, including tax and regulatory audits.
• Disruptions in the supply of components, raw materials, or finished products from third parties.
• Potential work stoppages or labor problems at manufacturing facilities.
• Interest rate risks associated with floating rate debt.
• The risk of products causing personal injury or adverse effects, leading to lawsuits and damages.
• The impact of changes in tax laws, including global minimum corporate tax rates and U.S. legislative changes.
• Risks related to the adoption and integration of artificial intelligence solutions.
• Interruptions, breakdowns, or breaches in information technology systems.

Future Outlook

The company expects its primary cash requirements for the period April 1, 2026 through December 31, 2026 to include debt repayments and interest of approximately $325 million and mandatory debt amortization payments of $21 million. Capital expenditures are expected to be approximately $185 million for property, plant, and equipment. The company anticipates continued investment in R&D for product development.

Management Comments

• Bausch + Lomb is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world—from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better.
• Bausch + Lomb understands that BHC continues to believe that completing the Separation, which may include the monetization of all or a portion of BHCs ownership interest in Bausch + Lomb, the sale of the Company (a Sale Transaction), the transfer of all or a portion of BHCs remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the Distribution), or a combination thereof, makes strategic sense and that BHC continues to evaluate all relevant factors and considerations related to completing the Separation, including those factors described in BHCs public filings.
• We believe that we have a significant innovation opportunity today. We have a robust global pipeline with projects in various stages of pre-clinical and clinical development, including new contact lenses for myopia, next-generation cataract equipment, premium IOLs, investigational treatments for dry eye, novel formulation for eye vitamins and preservative free formulation of eye drops, among others, that are designed to grow our portfolio and accelerate future growth.

Industry Context

StockSavvy.ai notes that Bausch + Lomb's performance in Q1 2026 reflects a broader trend in the eye health sector, with growth driven by innovation in contact lenses, pharmaceuticals for eye conditions, and surgical devices. The company's strategic focus on R&D and pipeline development aligns with industry demands for advanced treatments and improved patient outcomes.

Legal Proceedings

• Bausch + Lomb is involved in various legal and administrative proceedings, including product liability, intellectual property, commercial, tax, antitrust, governmental, and regulatory investigations.
• BHC and its subsidiaries are defendants in multidistrict antitrust litigation concerning generic pharmaceuticals pricing.
• BHC and its affiliates, including Bausch + Lomb, are named in product liability lawsuits involving the Shower to Shower body powder product.
• Bausch Health Americas is involved in a lawsuit with Doctors Allergy Formula, LLC, concerning a 2015 Asset Purchase Agreement.
• Bausch & Lomb Incorporated received notices of Paragraph IV Certification for Lumify patents, leading to infringement lawsuits against generic competitors.
• The company is involved in ongoing infringement proceedings related to Vyzulta and Lotemax SM products.

Related Party Transactions

• Amounts payable to BHC and its affiliates were $12 million as of March 31, 2026.
• Amounts due from BHC and its affiliates were $8 million as of March 31, 2026.
• The company entered into a Master Separation Agreement (MSA) with BHC in connection with the B+L IPO.
• A Transition Services Agreement (TSA) with BHC provided transitional administrative, HR, treasury, and support services.
• A Tax Matters Agreement governs tax liabilities, benefits, and proceedings between Bausch + Lomb and BHC.
• An Employee Matters Agreement governs employee-related liabilities, transfers, and equity awards.
• Other agreements with BHC include Intellectual Property Matters Agreement and Real Estate Matters Agreement.
• Charges incurred related to these agreements were $2 million for the three months ended March 31, 2026.

Stakeholder Impact

• Shareholders may see positive impact from revenue growth and improved financial performance.
• Employees may benefit from increased investment in R&D and potential growth opportunities.
• Customers may benefit from new product launches and continued availability of existing products.
• Creditors may be reassured by improved operating income and cash flow, though debt levels remain significant.

Next Steps

• Shareholders are being asked to approve a further amendment and restatement of the 2022 Omnibus Incentive Plan at the upcoming annual meeting.
• The company is continuing to evaluate strategic licensing and acquisition opportunities.
• The company is monitoring the impact of geopolitical events and macroeconomic conditions on its business.
• The company is continuing to evaluate the impact of the One Big Beautiful Bill Act on its financial statements.
• The company is continuing to monitor the separation from Bausch Health Companies Inc. (BHC).

Key Dates

Recommendation

While the Q1 2026 results show significant improvement in revenue and profitability, the company still operates at a net loss and carries substantial debt. The ongoing separation from BHC and numerous legal proceedings introduce considerable uncertainty. Therefore, a 'hold' recommendation is appropriate, pending further clarity on these strategic and legal matters.

Keywords

Bausch + Lomb, 10-Q, Quarterly Report, Eye Health, Vision Care, Pharmaceuticals, Surgical, Revenues, Net Loss, Operating Income, Financial Results, SEC Filing